|
1
|
Crino PB, Nathanson KL and Henske EP: The
tuberous sclerosis complex. N Engl J Med. 355:1345–1356. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weiner DM, Ewalt DH, Roach ES and Hensle
TW: The tuberous sclerosis complex: A comprehensive review. J Am
Coll Surg. 187:548–561. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Islam MP and Roach ES: Tuberous sclerosis
complex. Handb Clin Neurol. 132:97–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Inoki K, Corradetti MN and Guan KL:
Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet.
37:19–24. 2005. View
Article : Google Scholar
|
|
5
|
Curatolo P and Moavero R: mTOR Inhibitors
in Tuberous Sclerosis Complex. Curr Neuropharmacol. 10:404–415.
2012. View Article : Google Scholar :
|
|
6
|
Orlova KA and Crino PB: The tuberous
sclerosis complex. Ann N Y Acad Sci. 1184:87–105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang H, Cicchetti G, Onda H, Koon HB,
Asrican K, Bajraszewski N, Vazquez F, Carpenter CL and Kwiatkowski
DJ: Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt
signaling through downregulation of PDGFR. J Clin Invest.
112:1223–1233. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang H, Bajraszewski N, Wu E, Wang H,
Moseman AP, Dabora SL, Griffin JD and Kwiatkowski DJ: PDGFRs are
critical for PI3K/Akt activation and negatively regulated by mTOR.
J Clin Invest. 117:730–738. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carracedo A, Ma L, Teruya-Feldstein J,
Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma
SC, et al: Inhibition of mTORC1 leads to MAPK pathway activation
through a PI3K-dependent feedback loop in human cancer. J Clin
Invest. 118:3065–3074. 2008.PubMed/NCBI
|
|
10
|
Bissler JJ, McCormack FX, Young LR, Elwing
JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J,
et al: Sirolimus for angiomyolipoma in tuberous sclerosis complex
or lymphangioleiomyomatosis. N Engl J Med. 358:140–151. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Franz DN, Leonard J, Tudor C, Chuck G,
Care M, Sethuraman G, Dinopoulos A, Thomas G and Crone KR:
Rapamycin causes regression of astrocytomas in tuberous sclerosis
complex. Ann Neurol. 59:490–498. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nie J, Zhao C, Deng LI, Chen J, Yu B, Wu
X, Pang P and Chen X: Efficacy of traditional Chinese medicine in
treating cancer. Biomed Rep. 4:3–14. 2016.PubMed/NCBI
|
|
13
|
Liu J, Wang S, Zhang Y, Fan HT and Lin HS:
Traditional Chinese medicine and cancer: History, present
situation, and development. Thorac Cancer. 6:561–569. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang N, Kong X, Yan S, Yuan C and Yang Q:
Huaier aqueous extract inhibits proliferation of breast cancer
cells by inducing apoptosis. Cancer Sci. 101:2375–2383. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang X, Zhang N, Huo Q and Yang Q:
Anti-angiogenic and antitumor activities of Huaier aqueous extract.
Oncol Rep. 28:1167–1175. 2012.PubMed/NCBI
|
|
16
|
Wang X, Zhang N, Huo Q, Sun M, Lv S and
Yang Q: Huaier aqueous extract suppresses human breast cancer cell
proliferation through inhibition of estrogen receptor α signaling.
Int J Oncol. 43:321–328. 2013.PubMed/NCBI
|
|
17
|
Wu T, Chen W, Liu S, Lu H, Wang H, Kong D,
Huang X, Kong Q, Ning Y and Lu Z: Huaier suppresses proliferation
and induces apoptosis in human pulmonary cancer cells via
upregulation of miR-26b-5p. FEBS Lett. 588:2107–2114. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song X, Li Y, Zhang H and Yang Q: The
anticancer effect of Huaier (Review). Oncol Rep. 34:12–21.
2015.PubMed/NCBI
|
|
19
|
Kwiatkowski DJ, Zhang H, Bandura JL,
Heiberger KM, Glogauer M, el-Hashemite N and Onda H: A mouse model
of TSC1 reveals sex-dependent lethality from liver hemangiomas, and
up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol
Genet. 11:525–534. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu Z, Wang Y, Huang F, Chen R, Li C, Wang
F, Goto J, Kwiatkowski DJ, Wdzieczak-Bakala J, Tu P, et al:
Brain-expressed X-linked 2 is pivotal for hyperactive mechanistic
target of Rapamycin (mTOR)-mediated tumorigenesis. J Biol Chem.
290:25756–25765. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bravo-Cordero JJ, Hodgson L and Condeelis
J: Directed cell invasion and migration during metastasis. Curr
Opin Cell Biol. 24:277–283. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: New insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS,
Hwang SG, An S, Yoon G, Gye MC, Yi JM, et al: Claudin-1 induces
epithelial-mesenchymal transition through activation of the
c-Abl-ERK signaling pathway in human liver cells. Oncogene.
32:4873–4882. 2013. View Article : Google Scholar
|
|
27
|
van Kempen LC and Coussens LM: MMP9
potentiates pulmonary metastasis formation. Cancer Cell. 2:251–252.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Merdad A, Karim S, Schulten HJ, Dallol A,
Buhmeida A, Al-Thubaity F, Gari MA, Chaudhary AG, Abuzenadah AM and
Al-Qahtani MH: Expression of matrix metalloproteinases (MMPs) in
primary human breast cancer: MMP-9 as a potential biomarker for
cancer invasion and metastasis. Anticancer Res. 34:1355–1366.
2014.PubMed/NCBI
|
|
29
|
Teng Y, Ross JL and Cowell JK: The
involvement of JAK-STAT3 in cell motility, invasion, and
metastasis. JAKSTAT. 3:e280862014.PubMed/NCBI
|
|
30
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Du W, Hong J, Wang YC, Zhang YJ, Wang P,
Su WY, Lin YW, Lu R, Zou WP, Xiong H, et al: Inhibition of
JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via
mitochondrial pathway. J Cell Mol Med. 16:1878–1888. 2012.
View Article : Google Scholar
|
|
32
|
Judd LM, Menheniott TR, Ling H, Jackson
CB, Howlett M, Kalantzis A, Priebe W and Giraud AS: Inhibition of
the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and
in vivo. PLoS One. 9:e959932014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Uhlmann EJ, Apicelli AJ, Baldwin RL, Burke
SP, Bajenaru ML, Onda H, Kwiatkowski D and Gutmann DH:
Heterozygosity for the tuberous sclerosis complex (TSC) gene
products results in increased astrocyte numbers and decreased
p27-Kip1 expression in TSC2+/− cells.
Oncogene. 21:4050–4059. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ghosh S, Tergaonkar V, Rothlin CV, Correa
RG, Bottero V, Bist P, Verma IM and Hunter T: Essential role of
tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and
cell survival. Cancer Cell. 10:215–226. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zha X, Hu Z, Ji S, Jin F, Jiang K, Li C,
Zhao P, Tu Z, Chen X, Di L, et al: NFκB up-regulation of glucose
transporter 3 is essential for hyperactive mammalian target of
rapamycin-induced aerobic glycolysis and tumor growth. Cancer Lett.
359:97–106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bittmann I, Rolf B, Amann G and Löhrs U:
Recurrence of lymphangioleiomyomatosis after single lung
transplantation: New insights into pathogenesis. Hum Pathol.
34:95–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang F, Chen X, Li C, Sun Q, Chen Y, Wang
Y, Peng H, Liu Z, Chen R, Liu K, et al: Pivotal role of augmented
αB-crystallin in tumor development induced by deficient TSC1/2
complex. Oncogene. 33:4352–4358. 2014. View Article : Google Scholar
|
|
41
|
O'Shea JJ, Gadina M and Schreiber RD:
Cytokine signaling in 2002: New surprises in the Jak/Stat pathway.
Cell. 109(Suppl): S121–S131. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kiu H and Nicholson SE: Biology and
significance of the JAK/STAT signalling pathways. Growth Factors.
30:88–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nam S, Xie J, Perkins A, Ma Y, Yang F, Wu
J, Wang Y, Xu RZ, Huang W, Horne DA, et al: Novel synthetic
derivatives of the natural product berbamine inhibit Jak2/Stat3
signaling and induce apoptosis of human melanoma cells. Mol Oncol.
6:484–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Um HJ, Min KJ, Kim DE and Kwon TK:
Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of
human renal carcinoma Caki cells. Biochem Biophys Res Commun.
427:24–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Johnston PA and Grandis JR: STAT3
signaling: Anticancer strategies and challenges. Mol Interv.
11:18–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Goncharova EA, Goncharov DA, Damera G,
Tliba O, Amrani Y, Panettieri RA Jr and Krymskaya VP: Signal
transducer and activator of transcription 3 is required for
abnormal proliferation and survival of TSC2-deficient cells:
Relevance to pulmonary lymphangioleiomyomatosis. Mol Pharmacol.
76:766–777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mi R, Ma J, Zhang D, Li L and Zhang H:
Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in
treating a tuberous sclerosis complex cell model. J Genet Genomics.
36:355–361. 2009. View Article : Google Scholar : PubMed/NCBI
|
